EP1494696A4 - Behandlung von lungenerkrankungen - Google Patents

Behandlung von lungenerkrankungen

Info

Publication number
EP1494696A4
EP1494696A4 EP03728277A EP03728277A EP1494696A4 EP 1494696 A4 EP1494696 A4 EP 1494696A4 EP 03728277 A EP03728277 A EP 03728277A EP 03728277 A EP03728277 A EP 03728277A EP 1494696 A4 EP1494696 A4 EP 1494696A4
Authority
EP
European Patent Office
Prior art keywords
treatment
lung diseases
lung
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03728277A
Other languages
English (en)
French (fr)
Other versions
EP1494696A2 (de
Inventor
Kazunori Murakami
Perenlei Enkhbaatar
Lillian D Traber
Donald S Prough
David N Herndon
Daniel L Traber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Publication of EP1494696A2 publication Critical patent/EP1494696A2/de
Publication of EP1494696A4 publication Critical patent/EP1494696A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03728277A 2002-04-01 2003-03-25 Behandlung von lungenerkrankungen Withdrawn EP1494696A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36899702P 2002-04-01 2002-04-01
US368997P 2002-04-01
PCT/US2003/009053 WO2003084476A2 (en) 2002-04-01 2003-03-25 Treatment of lung disorder

Publications (2)

Publication Number Publication Date
EP1494696A2 EP1494696A2 (de) 2005-01-12
EP1494696A4 true EP1494696A4 (de) 2006-01-25

Family

ID=29420316

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03728277A Withdrawn EP1494696A4 (de) 2002-04-01 2003-03-25 Behandlung von lungenerkrankungen

Country Status (10)

Country Link
US (1) US20090221475A9 (de)
EP (1) EP1494696A4 (de)
JP (2) JP2005527570A (de)
KR (2) KR20040105838A (de)
CN (1) CN100384469C (de)
AU (3) AU2003233428B2 (de)
CA (1) CA2480790A1 (de)
IL (2) IL164078A0 (de)
NZ (1) NZ535487A (de)
WO (1) WO2003084476A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
WO2012051339A2 (en) * 2010-10-12 2012-04-19 Vetgel Technologies Methods and compositions for treating respiratory conditions using platelet enriched plasma
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
US10174110B2 (en) 2013-02-13 2019-01-08 Laboratoire Français Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-α antibodies and uses thereof
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160029840A (ko) 2013-07-05 2016-03-15 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 친화성 크로마토그래피 매트릭스
JP6779866B2 (ja) 2014-06-13 2020-11-04 チルドレンズ メディカル センター コーポレイション ミトコンドリアを単離するための製品および方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2020214644A1 (en) * 2019-04-15 2020-10-22 Children's Medical Center Corporation Aerosolized compositions comprising mitochondria and methods of use thereof
JP2024509735A (ja) * 2021-02-17 2024-03-05 ユニヴァーシティ オヴ ロチェスター 敗血症の予後を処置、診断及び予測する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019701A2 (en) * 1995-11-30 1997-06-05 Hamilton Civic Hospitals Research Development, Inc. Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
EP1273305A1 (de) * 2001-07-06 2003-01-08 Aventis Behring GmbH Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08782B2 (ja) * 1986-11-22 1996-01-10 株式会社ミドリ十字 抗炎症剤
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
JPH06256213A (ja) * 1993-03-03 1994-09-13 Green Cross Corp:The ヒト由来アンチトロンビン−ｉｉｉの医薬用途
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
IL142639A0 (en) * 1998-10-20 2002-03-10 Childrens Hosp Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019701A2 (en) * 1995-11-30 1997-06-05 Hamilton Civic Hospitals Research Development, Inc. Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
EP1273305A1 (de) * 2001-07-06 2003-01-08 Aventis Behring GmbH Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS

Also Published As

Publication number Publication date
WO2003084476A2 (en) 2003-10-16
IL164078A0 (en) 2005-12-18
CN1774258A (zh) 2006-05-17
IL164078A (en) 2011-02-28
KR20040105838A (ko) 2004-12-16
US20040192595A1 (en) 2004-09-30
AU2011236070A1 (en) 2011-11-03
EP1494696A2 (de) 2005-01-12
CN100384469C (zh) 2008-04-30
NZ535487A (en) 2008-12-24
US20090221475A9 (en) 2009-09-03
JP2005527570A (ja) 2005-09-15
AU2003233428A1 (en) 2003-10-20
CA2480790A1 (en) 2003-10-16
KR20100117148A (ko) 2010-11-02
WO2003084476A3 (en) 2004-04-22
JP2011225625A (ja) 2011-11-10
AU2008243077A1 (en) 2008-11-27
AU2003233428B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
FIU20060389U0 (fi) Luusairauksien hoito
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60325353D1 (de) Behandlung von mukositis
EP1494696A4 (de) Behandlung von lungenerkrankungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
ATE369136T1 (de) Therapeutische behandlung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20051209

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/06 19800101ALI20051205BHEP

Ipc: A61P 11/00 20000101ALI20051205BHEP

Ipc: A61K 38/00 19950101ALI20051205BHEP

Ipc: A61K 9/00 19680901AFI20051205BHEP

17Q First examination report despatched

Effective date: 20060505

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120327